INZY - Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
2024-03-08 14:45:31 ET
Summary
- 48-week results from the phase 1/2 studies, using INZ-701 for the treatment of patients with ENPP1 Deficiency and ABCC6 Deficiency, expected in Q1 2024.
- Results from the phase 3 ENERGY-3 study, using INZ-701 for the treatment of patients with ENPP1 Deficiency, expected in mid-2025.
- An expansion opportunity exists for this company, which would be the advancement of INZ-701 for calciphylaxis that occurs in patients with end-stage kidney disease receiving hemodialysis.
- Initiation of phase 1 SEAPORT-1 study, using INZ-701 for calciphylaxis that occurs in patients with end-stage kidney disease receiving hemodialysis expected in 1st half 2024; Interim data Q4 of 2024.
Inozyme Pharma ( INZY ) is a biotech to watch because it is making traction on advancing its drug INZ-701 for the treatment of patients with rare diseases. Two programs, where progress has been made, would be the use of this drug to treat patients with ENPP1 Deficiency and ABCC6 Deficiency. There is an ongoing phase 3 pivotal study known as ENGERGY-3, which is using INZ-701 for the treatment of pediatric patients with ENNP1 Deficiency. Even though this catalyst is not set to have results released from it until mid-2025, that doesn't mean that there won't be other catalysts in 2024 in the meantime to increase shareholder value. For instance, in Q1 of 2024 it is expected that topline data from the phase 1/2 Adult study using INZ-701 for the treatment of ENPP1 Deficiency, will be released in Q1 of 2024. From there, there are additional catalysts relating to this ENPP1 Deficiency program....
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward